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Abstract. There are many pathogen microbial species with very different antimicrobial drugs susceptibility. 
In this work, we selected pairs of antifungal drugs with similar/dissimilar species predicted-activity profile 
and represented it as a large network, which may be used to identify drugs with similar mechanism of action. 
Computational chemistry prediction of the biological activity based on quantitative structure-activity 
relationships (QSAR) susbtantialy increases the potentialities of this kind of networks avoiding time and 
resources consming experiments. Unfortunately, almost QSAR models are unspecific or predict activity 
against only one species. To solve this problem we developed here a multi-species QSAR classification 
model, which outputs were the inputs of the above-mentioned network. Overall model classification accuracy 
was 87.0% (161/185 compounds) in training, 83.4% (50/61) in validation, and 83.7% for 288 additional 
antifungal compounds used to extent model validation for network construction. The network predicted has 59 
nodes (compounds), 648 edges (pairs of compounds with similar activity), low coverage density d = 37.8%, 
and distribution more close to normal than to exponential. These results are more characteristic of a not-over-
estimated random network, clustering different drug mechanisms of actions, than of a less useful power-law 
network with few mechanisms (network hubs).  
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Introduction 
There is a high interest on the search of rational approaches for antimicrobial drugs discovery. In particular, 
fungi-caused infections have increased dramatically during the past decades. Systemic mycoses mainly appear 
concomitant with other diseases or are caused by treatment with chemotherapeutics, for instance with 
cytostatics. At risk are patients after organ transplantation treated with immunosuppressives or those suffering 
with a weakened immune system, for example patients with AIDS. In this sense, quantitative structure-
activity relationships (QSAR) studies may play an important role. Disappointingly, QSAR studies are 




There are more than 1 600 molecular descriptors that may be in principle generalized and used to solve the 
former problem.
4
 In any case, no one of  these indices have been extended yet to encode information 
additional to chemical structure.
5-7
 Our group has introduced elsewhere a Markov model (MM) method named 
MARCH-INSIDE, MARkovian CHemicals IN SIlico Design. AMRCH-INSIDE use matrix invariants such as 
stochastic entropies and spectral moments for the study of molecular properties.
8-10
 Stochastic spectral 
moments have been used for QSAR problems including the design of antimicrobial and anticancer drugs as 
well as for RNA and proteins QSAR problems.
11-15
 Otherwise, entropy like parameters has demonstrated 
flexibility to treat many problems.
16-20
 In recent studies the MARCH-INSIDE method has been extended to 
encompass molecular environment information in addition to molecular structure calculating thermodynamic 
free energy for many physicochemical and biological processes.
21,22
 This approach take into consideration the 




In fact, there are many pathogen microbial species whith very different antimicrobial drugs susceptibility. 
This very high number of drug-species combinations may be investigated using networks to group or cluster 
drugs with similar multi-species activity profile and possibliy mechanism of action. We can use different 
classes of networks such as: artifical neural networks (ANN) 
25-36
 to mining datasets, depicting relationships 
between within the genetic code,
37-43
 or representing relationships between proteins, genes, RNAs, organisms, 
or even non-living objects.
44-58
 Specifically, co-expression networks can be constructed by measuring the 
expression of pairs or genes in different tissues.
59-63
 Similarly, protein networks can be constructed from pair-
wise experimentally or theoretically stablished protein-protein interactions.
44,64-66
 In co-expression networks 
two RNAs are connected (supposed to be involved in common mechanism of regulation) if the levels of both 
RNAs for different tissues strongly correlate.
67
 We propose to use the same network approach to study mulit-
species antimicrobials drug action. In this case, the antimicrobial drug plays the role of the RNA molecule and 
the drug activity against different species activity play the role of RNA level of expression in different tissues. 
In the co-expression network we need to measure each RNA tissue profile if we do not have a computational 
approach to predict it.
59,68
 For antimicrobials networks; we need to measure the activity of the drug against 
different species. Consequently, the QSAR method used for antimicrobials multi-species network construction 
must be able to make multi-species prediction of the antimicrobial activity. 
In this work, we selected by the first time pairs of antifungal drugs with similar/dissimilar multi-species 
predicted-activity profile and represented it as a large network, which may be used to identify drugs with 
similar mechanism of action. First, we developed a multi-species QSAR classification model, which ouputs 
were the inputs of the above-mentioned network. Next, we used the outputs of this QSAR model to construct 
a network with low coverage density and normal-like distribution for antifungal compounds having similar 
multi-species activity. These results are more characteristic of a not-over-estimated random network, 
clustering different drug mechanisms of actions, than of a less useful power-law network with few 
mechanisms (network hubs).
69
 We illustrate the use of the network for azole drugs such as voriconazole, 
miconazole, fluconazole and others. The present work reports by the first time the use of QSAR 
computational techniques to construct multi-species activity networks for antimicrobial drugs. 
Materials and methods 
Absolute probabilities for drug-target step-by-step interaction 
By using, Chapman-Kolgomorov equations we can calculate the absolute probabilities 
A
πk(j,s) for the 
interaction in many step of different j-th atoms with the receptors in different microbial species (s). The 
A
πk(j,s) can be determined as the elements of the vectors 
k
π(s). These vectors are elemnts of a Markov chain 
based on the stochastic matrix 
1
Π, which describes conditional probabilities of interaction of the j-th atom 
given that previously other i-th atom has interacted with the receptor. The theoretic foundations of the 






































πk(j,s) can be summed for specific sets of atoms (AS) to create local molecular descriptors  for the 
drug-target interaction. Herein the AS used were: halogens (X), insaturated carbons (Cins), saturated carbons 
(Csat), heteroatoms (Het), and hydrogens bound to heteroatoms (H-Het). The corresponding symbols of the 










πk(H-Het,s). In this 




 Statistical analysis 
As a continuation of the previous sections, we can attempt to develop a simple linear QSAR using the 












Here, the absolute probabilities 
A
πk(C,s) play the role of molecule-target interaction descriptors for specific 
microbial species. We selected Linear Discriminant Analysis (LDA)
70 
to fit the classification functions. The 
model deals with the classification of a set of compounds as active or not against different microbial species. 
A dummy variable (Actv) was used to codify the antimicrobial acitivity. This variable indicates either the 
presence (Actv = 1) or absence (Actv = –1) of antimicrobial activity of the drug against the microbe species in 
question. In equation (8), bk represents the coefficients of the classification function, determined by the LDA 
module of the STATISTICA 6.0 software package
71
 using forward stepwise strategy for variable 
selection.The quality of LDA models was determined by examining Wilk’s U statistic, Fisher ratio (F), and 
the p-level (p). We also inspected the percentage of good classification. Validation of the model was 
corroborated with external prediction series.
22
  
 Data set  
The data set was conformed by a set of marketed and/or very recently reported antifungal drugs which low 
reported MIC50 < 10 μM against different fungus. The three data sets used were as follows training series: 107 
active compounds plus 78 non-active compounds (185 in total); predicting series: 36 + 74 = 110 in total; 
virtuals screening 288 active compounds. The literature reports experimental test of each drug against some 
but not all species of a list of 87. In consequence we were able to collect 583 cases (drug/species pairs). The 
names or codes for all compounds are depicted in Table 1SM (upon request to authors) of the supplementary 






In order to perform the antimicrobials multi-specie activity with a network approach we carried out the 
following steps:  




2. We calculated the scores of biological activity of each one of the 59 drugs against all the fungus species 




3. All the activity scores predicted were organized into a Table of drugs (rows) vs. species (columns), 
which was used as input for the software STATISTICA employed to calculate drug-drug multispecies 
correlations in the form of Pearson r coefficients. These correlations were represented actually as distances (1- 
Pearson r) between drugs pairs. The Pearson distance matrix was derived using the software package 
STATISTICA.
71
   
4. Using Microsoft excel73 again we transformed the drug pair distances matrix derived with Statistic into 
into a Boolean matrix. The elements of this matrix are equal to 1 if two drugs have a high correlation or the 
same are very close (short distance (1-Pearson r)). The threshold value used was a distance of 0.005. The line 
command used in Excel to transform the distance matrix into a Boolean matrix was f = if (A$1=$B2,0, if 
(B2>0.0051, 0, 1)). It allows transforming distance into Boolean values and equals the main diagonal 
elements to 0 avoiding loops in the future network. The Boolean matrix was saved as a txt format file. 
5. After, renamed the .txt file as a .mat file we read it with the software CentiBin.74,75 Using CentiBin we 
can not only represent the network but also highlight all drugs (nodes) connected to a specific drug and 
calculating many parameters including node degree. 
6. The ChemOffice software76 was used to draw and calculate topological indices (TIs): network radius 
(Ri), network diameter (Di), sum of vertex degrees network radius (δi), and Wiener index (W) for small 
networks used in the example of related to Table 1. The loops (LPi) or hub presence (HPi) were easily 
calculated by visual inspection. Details on the definition of TIs and their uses for small molecules, 
macromolecules and complext networks can be found in the literature.
1,77-79
  
7. CentiBin software was used to generate random networks by five different algorithms including: 
Barabasi-Albert random network, Kleinberg small wolrd network (SWN), 2D Lattice network, Erdos-Renyi 




8. Last, all node degrees were used as input in STATISTICA in order to study the distribution of the 




Results and discussion 
Training and validation of the model 
This work introduces by the first time a single linear QSAR equation model to predict the antifungal activity 







Where, Rc it is the canonical regression coefficient, λ it is the Wilk’s statistics; and p the error level. In this 
equation, the absolute probabilities 
A
πk calculated refers to:  
1. Aπ5(s, CSp & Sp2) all unsaturated Carbon atoms (Sp and Sp2 atoms) and all atoms placed at five or 
least atoms from them. 
2.  Aπ0(s,X) all halogens atoms. 
3. Aπ0(s, H-Het) all Hydrogen atoms bound to a Heteroatom (N, O, or S). 
      The model, with only three variables, correctly classifies 90 out of 107 active compounds (84.1%) and 
71 out of 78 non-active compounds (91.02%). Overall training accuracy was 87.02% (161 out of 185 
compounds). Validation of the model was carried out by means of external predicting series. The model 
correctly classifies 30 out of 36 active compounds (83.3%) and 20 out of 25 non-active compounds (80.0%) in 
prediction series. Overall predictability was 83.38% (50 out of 61 compounds). Values in the range of 80 to 
100 % are accepted as high accuracy for many authors that reported QSAR models based on LDA, including 
unique-specie antimicrobial QSAR models.
6,80-88
 The present is the first model to predict the antifungal 
activity of any organic compound against a very large diversity of species based on molecular MM absolute 
probabilities, hence considering that the present is a multi-species QSAR the result is very good. The Figure 1 
illustrates this idea depicting overall prediction of the biological activity of broad spectrum antifungal drugs.  
Two possible applications for the present model are the biomolecular screening of antifungals active against 
different species and the construction of multi-species activity profile networks for antifungals. In both cases, 
species susceptibility identification is imperative. For instance, the model recognizes 100% of the species 
studies that can be treated with ketoconazole. Detailed information on the names, predicted classification, and 
probability of action against different species of the drugs used to seek the model appear in Table 1SM of the 
supplementary material. The details of the forward-stepwise process for variable selection appear in the Table 
2SM of the same supplementary material (upon request to authors). 
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Figure 1. Overall prediction of the biological activity of broad spectrum antifungal drugs. 
 
Computational chemistry based virtual screening experiment  
A model for multi-species screening of antifungals and construction of multi-species activity profile 
networks necessarily have to be based on as diverse as possible series of chemical structural patterns. The 
compounds used to seek the model are structurally heterogeneous. However, in order to offer additional 
evidence on the validity of the model and also show how to use it in practice we carried out a virtual screening 
experiment. In this study, we try to predict the result of 288 positive activity tests for different compounds 
with diverse species. These results where never used in training or predicting series above. The model was 
able to correctly predict 241 out of 288 tests (83.68%). All these results were depicted in detail on Table 2SM 
of supplementary material (upon request to authors). Finally, the high potential of the present model to select 
 6 
broad spectrum antifungal drugs can be illustrated also from the point of view of prediction of species 
multidrug susceptibility. The Figure 2 depicts some selected values of the overall prediction of the antifungal 
drug susceptibitliy of selected species. For instance the model identifies 80.0% of the drugs that can be used 
to control Candida spp. 
 
Figure 2. Overall prediction of the antifungal drug susceptibitliy of selected species. 
 
Network approach to multi-species activity profile of antifungal drugs  
First, used the multi-species QSAR predict the biological activity of 59 antifungal drugs against all the 
species studied. After correlation of activity score predicted with the QSAR equation of all possible pairs of 
drugs we decided which pairs of drugs have similar or dissimilar activity profile. The network has 59 nodes 
(compounds). We can determine a correlation threshold at which two genes are assessed to be co-expressed 
using a clustering coefficient.
89
 We applied the same reckoning to pairs of antifungal drugs and decided the 
pairs of compounds connect to each other within the network after tree joining cluster analysis based on the 1- 
Pearson r. The Figure 3 illustrates the tree joining formation of different clusters of compounds at different 
distances. The use of Tree joining clustering have been well documented in QSAR for clustering of 





Figure 3. Clustering of antifungals drugs based on predicted species susceptibilities 
 
We decided to use as threshold value for dissimilarity between the multi-species activities of two drugs the 
value distance-treshold = 0.0051. This threshold distance value was selected after inspection of the sinlge-
linkage clustering of compounds in order to avoid network overcrowding. The Figure 4 illustrates the 
distribution of drug-drug activity dissimilarity across linking steps for pairs of drugs. Using the combinatorial 
formula
88
 we can calculate n!/[(n -2)!·2!] = 59!/(57! ·2!) = 59·58·57!/(57! ·2!) = (59·58)/2 = 1711 possible 






Figure 4. Plot of linkage distances across steps 
 
Our multi-species QSAR predict 648 pairs of drugs with similar activity (dissimilarity lower than 0.0051) 
out of the 17711 possible pairs. So, we can predict low network edges coverage density d = 648/1711 = 
37.9%.
92,93
 Having a relatively low d is very important to avoid a netwrok that over-stimates thenumber of 
mechanism of actions for a drug or simply give so many possible mechanism to be investigated that becomes 
missuseful the prediction. The Figure 5 depicts an overall representation of the present network in the 
CentiBin software interface.
94
 We also give an example on the use of the network for the identification of 
similar mechanism of action for azole class of durgs such as: voriconazole, miconazole, fluconazole and 
others. Azole class is one of the more classic classes of anifungal drugs but the the synthesis, testing and 





Figure 5. Antifungal drugs similar-mechanism-of-action network. 
 
The accuracy of the model in terms of the percentages of good classification of active/non-active drugs is 
very important for network construction but is not the only aspect to be considered. However, the final 
topology of the network we pretend to construct is at less as important as model accuracy for inference of 
drugs multi-species activity similariy. For instance, we can find two models with the same overall accuracy 
but predicting networks with topological properties essentially different. In general, different methods for 
network reconstruction based on co-expresion not give as result the same network.
96
 In Table 1 we illustrate 
this fact with a hypothetic example. In this example we have a real network and four models derived to 
reconstruct it. The four models predict correctly the same number of drug similarities so they have the same 
accuracy. Nevertheless, the topologies predicted are in some cases very different each other and with respect 
to the real network too. For instance, the real network presents a central node (network hub),
69
 which 






Table 1. Comparing real network and four models 
TIsa Valueb Differencec 
(1)  
 
Valueb Differencec TIsa 
R1 1 0 5 4 R3 
D1 2 0 5 3 D3 
δ1 20 20 20 20 δ3 
W1 100 10 125 35 W3 
LP1 No Yes Yes No  LP3 






TIsa Valueb Differencec 
(4) 
  
Valueb Differencec TIsa 
R2 5 4 4 3 D4 
D2 10 8 2 0 R4 
δ2 20 20 20 20 δ4 
W2 220 130 140 50 W4 
LP2 No Yes No Yes LP4 
HP2 No Yes Yes No HP4 
a
 Topological indices (TIs) used to characterize the topology of the example-real network (center of the table) and networks predicted 
with hypothetic QSAR models: (1)-regular star with arms of length 1, (2)-linear, (3)-loop, (4)-regular star with arms of length 2; the 
TIs used were: network radius (Ri), network diameter (Di), sum of vertex degrees network radius (δi), Wiener index (W) and loop 
(LPi) or hub presence (HPi). The values of the TIs for the example-real network are R = 1, D = 2, δ = 40, W = 90, LP = Yes and HP = 
Yes. 
b
 Value: is the value of the given TIs for the corresponding network. 
c
 Difference: is the difference between the value of the TIs 
for the predcted network and the value of the TIs for the example-real network.  
 
Consequently, any other drug wihin the network present possibly the same mechanisn of action. The only 
one predicted network that reproduces this topology is the network (1) with a regular star topology having 
arms of length 1. By the contrary, the network (3) is a loop and predict that any drug in the network have the 
same mechanism as hub, which becomes in this case and isolated drug.
97
 Consequently, in addition to QSAR 
model accuracy we should measure the topology of the network predicted and compare it with other known 
networks. It makes possible to derive general conclusions on the line of thinking above expressed. In the 
example of the Table 1 we used different continuos and dummy measures of network topology such as the 
 11 
Diameter (D, longest path), Radius (R, shortest path), the sum of node degrees (δ), the Wiener index (W), and 
presence of loops (PL) or hubs (HP).
92,98-100
 We carried out a similar anlysis comparing the network predicted 
in this work with other recognized models of ideal networks. In the Table 2 we illustrate the results of this 
analysis. 
 
Table 2 Comparison with some ideal random network models 
Antifungal drugs  
 multi-species-activity QSAR network 
Value TIs Value Barabasi Albert Random Network 
 
59 n 59 
 
648 m 631 
6808 W 5582 
6 D 2 
5.13 R 1.42 
22 δ 21 
1.99 Dist 1.63 
0.009 C 0.011 
0.26 E 0.5 
0.144 λ 0.123 
2D Lattice Network Value TIs Value Kleinberg Small World Network 
 
64 n 64 
 
128 m 192 
16384 W 10438 
8 D 4 
5.07 R 2.49 
4 δ 6 
4.06 Dist 2.58 
0.004 C 0.006 
0.12 E 0.25 
0.125 λ 0.122 
Erdos Renyi Random Network Value TIs Value Epsstein Power Law Network 
 
59 n 59 
 
640 m 648 
5554 W 5548 
2 D 2 
1.43 R 1.43 
22 δ 22 
1.63 Dist 1.62 
0.01 C 0.01 
0.50 E 0.50 
0.128 λ 0.128 
a 
The TIs used are: number of nodes (n), number of edges (m), Wiener index (W), diameter (D), and the network average values for 
radiality (R), node degree (δ), topological distance (Dist), node closeness (C), eccentricity (E) and node eigenvector value (λ). 
 12 
    We generated 5 ideal networks, one of each of the follwing classes: Barabasi-Albert random network, 
Kleinberg small wolrd network (SWN), 2D Lattice network, Erdos-Renyi network and Epsstein power law 
network (PLN).
75,101-103
 The general topologic properties of these classes of networks have been studied in detail 
before. Consequently, if we pretend to study the features of our actual network, which characterize multi-
species antifugal activity of drugs, could interesting to select between these networks the more similar to our 
actual network an study the deviations of the actual with respect to ideal behaviour. The networks were 
generated as similar a possible to actual. We measure 10 network features including: number of nodes (n), 
number of edges (m), Wiener index (W), diameter (D), and the network average values for radiality (R), node 
degree (δ), topological distance (Dist), node closeness (C), eccentricity (E) and node eigenvector value (λ). The 
description of these kind of parameters have been reported previously
94
 and the applications for small 
molecules, macromolecules, and networks reviewed.
79
 The deviation of the actual network with respect to ideal 
behaviour was measured in terms of Relative Difference Percentage (RD%) as follows RD% = (TI actual – 
TIi)·100/ TI actual (see Table 2 and Table 3).  
 
Table 3. Summary of the comparative study of the actual vs. ideal networks 







N 59 59 64 64 59 59 
M 648 631 128 192 640 648 
W 6808 5582 16384 10438 5554 5548 
D 6 2 8 4 2 2 
R 5.13 1.42 5.07 2.49 1.43 1.43 
Δ 22 21 4 6 22 22 
Dist 1.99 1.63 4.06 2.58 1.63 1.62 
C 0.009 0.011 0.004 0.006 0.01 0.01 
E 0.26 0.5 0.12 0.25 0.5 0.5 
Λ 0.144 0.123 0.125 0.122 0.128 0.128 
Relative Difference % = (TI actual – TIi)·100/ TI actual 
N - 0 -8.5 -8.5 0 0 
m - 2.6 80.2 70.4 1.2 0 
W - 18.0 -140.7 -53.3 18.4 18.5 
D - 66.7 -33.3 33.3 66.7 66.7 
R - 72.3 1.2 51.5 72.1 72.1 
δ - 4.5 81.8 72.7 0 0 
Dist - 18.1 -104.0 -29.6 18.1 18.6 
C - -22.2 55.6 33.3 -11.1 -11.1 
E - -92.3 53.8 3.8 -92.3 -92.3 
λ - 14.6 13.2 15.3 11.1 11.1 
Summary statistics 
Mean 8.23 -0.07 18.89 8.42 8.36 
Standard Deviation 45.83 75.34 41.61 45.18 45.22 
Closer to 0 0 1.2 3.8 0 0 
Max 72.3 81.8 70.4 66.7 72.1 
Min -92.3 -140.7 3.8 -92.3 -92.3 
Absolute Values Mean 31.13 57.23 37.17 29.10 29.04 
SD for AVM 33.15 45.12 24.34 34.34 34.43 
 13 
a 
The TIs used are: number of nodes (n), number of edges (m), Wiener index (W), diameter (D), and the network average values for 
radiality (R), node degree (δ), topological distance (Dist), node closeness (C), eccentricity (E) and node eigenvector value (λ). 
 
 
All networks present no more than 5 nodes than the actual with RD% lower than 10% in all cases. With 
respect to the number of edges all present the same or lower covering than the actual being any prediction in 
this sense non-over-estimated. The lower differences (more similar networks) for different features were: 
Epsstein PLN for m (RD% = 0%), Barabasi-Albert for W (18.0%), Erdos-Renyi and Epsstein PLN for δ (0%), 
2D Lattice for R (1.2), Barabasi-Albert and Erdos-Renyi for Dist (18.1),  Erdos-Renyi and Epsstein PLN for C 
(-11.1%), Kleinberg SWN for E (3.8%), and Erdos-Renyi and Epsstein PLN for (λ). Any network resembles 
significantly, in terms of D, to the actual (D = 6). However, we find a sort of upper and lower limits for actual 
network in the Kleinberg SWN and 2D Lattices which present D values of 4 and 8 having an RD% of 33.3 
and -33.3% respectively. In closing, the actual network does not exactly match with any of ideal behaviours 
studied but, as usuall in the real world, have different properties of these ideal networks. This fact can be 
corroborated studinying the node degree distribution of the actual network. The Figure 6 illustrates that the 
present network, even more close to normal distribution, does not significantly fit to normal, exponential, chi-
square or gamma distributions. These results points to a not-over-covered normal random network, clustering 
different drug mechanisms of actions. The network is more far from a less useful (in this case) exponential 





Figure 6. Distribution fitting study for antifungals similar-mechanism-of-action network, Kolmogorov-Smirnov 
difference d values are: d(Normal) = 0.097, d(Chis-Sqr) = 0.181 d(Gamma) = 0.201, d(Exponential) = 0.241 in 




Using the MARCH-INSIDE approach is possible to seek a useful QSAR classifier for active/non-active 
drugs, which scores multi-species antifungal activity of chemicals. In analogy with gene, and transcripts co-
expresion network we used the QSAR model outputs to derived a large network clustering antifungal drugs in 
terms of similar multi-species activity profile. Comparative studies reveal that the present network apparently 
has not an ideal behaviour but resemble some known network models in different aspects. In this sense, the 
network do not fit to some tested known distributions but is more close to normal than to exponential. These 
results are more characteristic of a not-over-estimated random network, clustering different drug mechanisms 
of actions. The present work reports by the first time the use of QSAR computational techniques in the 




Gonzalez-Díaz H. acknowledges contract/grant sponsorship from the Program Isidro Parga Pondal of the 
“Dirección Xeral de Investigación y Desenvolvemento” of “Xunta de Galicia”. This author also acknowledges 
two contracts as guest professor in the Department of Organic Chemistry, Faculty of Pharmacy, University of 
Santiago de Compostela, Spain in 2006. The authors thank the Xunta de Galicia (projects PXIB20304PR and 
BTF20302PR) and the Ministerio de Sanidad y Consumo (project PI061457) for partial financial support.  
 15 
References 
1. Todeschini, R.; Consonni, V. Handbook of Molecular Descriptors; Wiley-VCH, 2002. 
2. Otzen, T.; Wempe, E. G.; Kunz, B.; Bartels, R.; Lehwark-Yvetot, G.; Hansel, W.; Schaper, K. J.; 
Seydel, J. K. J Med Chem 2004, 47(1), 240-253. 
3. Fratev, F.; Benfenati, E. J Chem Inf Model 2005, 45(3), 634-644. 
4. Kubinyi, H. J Cancer Res Clin Oncol 1990, 116(6), 529-537. 
5. Marrero-Ponce, Y.; Medina-Marrero, R.; Torrens, F.; Martinez, Y.; Romero-Zaldivar, V.; Castro, E. A. 
Bioorg Med Chem 2005, 13(8), 2881-2899. 
6. Marrero-Ponce, Y.; Castillo-Garit, J. A.; Olazabal, E.; Serrano, H. S.; Morales, A.; Castanedo, N.; 
Ibarra-Velarde, F.; Huesca-Guillen, A.; Sanchez, A. M.; Torrens, F.; Castro, E. A. Bioorg Med Chem 
2005, 13(4), 1005-1020. 
7. Marrero-Ponce, Y.; Montero-Torres, A.; Zaldivar, C. R.; Veitia, M. I.; Perez, M. M.; Sanchez, R. N. 
Bioorg Med Chem 2005, 13(4), 1293-1304. 
8. González-Díaz, H.; Olazabal, E.; Castanedo, N.; Sanchez, I. H.; Morales, A.; Serrano, H. S.; Gonzalez, 
J.; de Armas, R. R. J Mol Model (Online) 2002, 8(8), 237-245. 
9. González-Díaz, H.; Gia, O.; Uriarte, E.; Hernadez, I.; Ramos, R.; Chaviano, M.; Seijo, S.; Castillo, J. A.; 
Morales, L.; Santana, L.; Akpaloo, D.; Molina, E.; Cruz, M.; Torres, L. A.; Cabrera, M. A. J Mol Model 
2003, 9(6), 395-407. 
10. González-Díaz, H.; Sanchez, I. H.; Uriarte, E.; Santana, L. Comput Biol Chem 2003, 27(3), 217-227. 
11. González-Díaz, H.; de Armas, R. R.; Molina, R. Bull Math Biol 2003, 65(6), 991-1002. 
12. González-Díaz, H.; Uriarte, E.; Ramos de Armas, R. Bioorg Med Chem 2005, 13(2), 323-331. 
13. González-Díaz, H.; Molina, R.; Uriarte, E. Bioorg Med Chem Lett 2004, 14(18), 4691-4695. 
14. González-Díaz, H.; de Armas, R. R.; Molina, R. Bioinformatics 2003, 19(16), 2079-2087. 
15. González-Díaz, H.; Saiz-Urra, L.; Molina, R.; Gonzalez-Diaz, Y.; Sanchez-Gonzalez, A. J Comput 
Chem 2007, 28(6), 1042-1048. 
16. Ramos de Armas, R.; González-Díaz, H.; Molina, R.; Perez Gonzalez, M.; Uriarte, E. Bioorg Med 
Chem 2004, 12(18), 4815-4822. 
17. Ramos de Armas, R.; González-Díaz, H.; Molina, R.; Uriarte, E. Proteins 2004, 56(4), 715-723. 
18. González-Díaz, H.; Bastida, I.; Castanedo, N.; Nasco, O.; Olazabal, E.; Morales, A.; Serrano, H. S.; de 
Armas, R. R. Bull Math Biol 2004, 66(5), 1285-1311. 
19. González-Díaz, H.; Marrero, Y.; Hernandez, I.; Bastida, I.; Tenorio, E.; Nasco, O.; Uriarte, E.; 
Castanedo, N.; Cabrera, M. A.; Aguila, E.; Marrero, O.; Morales, A.; Perez, M. Chem Res Toxicol 2003, 
16(10), 1318-1327. 
20. González-Díaz, H.; Aguero, G.; Cabrera, M. A.; Molina, R.; Santana, L.; Uriarte, E.; Delogu, G.; 
Castanedo, N. Bioorg Med Chem Lett 2005, 15(3), 551-557. 
21. González-Díaz, H.; Cruz-Monteagudo, M.; Molina, R.; Tenorio, E.; Uriarte, E. Bioorg Med Chem 2005, 
13(4), 1119-1129. 
22. Cruz-Monteagudo, M.; González-Díaz, H.; Agüero-Chapin, G.; Santana, L.; Borges, F.; Domínguez, R. 
E.; Podda, G.; Uriarte, E. J Comput Chem 2007, doi:10.1002/jcc.20730. 
23. González-Díaz, H.; Prado-Prado, F. J.; Santana, L.; Uriarte, E. Bioorg Med Chem 2006, 14 5973–5980. 
24. Prado-Prado, F.; González-Díaz, H.; Santana, L.; Uriarte, E. Bioorg Med Chem                       2007, 15
 897-902. 
25. Katritzky, A. R.; Dobchev, D. A.; Fara, D. C.; Karelson, M. Bioorg Med Chem 2005, 13(24), 6598-
6608. 
26. Basak, S. C.; Grunwald, G. D.; Gute, B. D.; Balasubramanian, K.; Opitz, D. J Chem Inf Comput Sci 
2000, 40(4), 885-890. 
27. Baskin, II; Ait, A. O.; Halberstam, N. M.; Palyulin, V. A.; Zefirov, N. S. SAR QSAR Environ Res 2002, 
13(1), 35-41. 
28. Benigni, R.; Giuliani, A. Mutat Res 1994, 306(2), 181-186. 
29. Fernandez, M.; Caballero, J. J Mol Graph Model 2006. 
30. Fernandez, M.; Caballero, J.; Tundidor-Camba, A. Bioorg Med Chem 2006, 14(12), 4137-4150. 
 16 
31. Fernandez, M.; Tundidor-Camba, A.; Caballero, J. J Chem Inf Model 2005, 45(6), 1884-1895. 
32. Fernandez, M.; Caballero, J.; Helguera, A. M.; Castro, E. A.; Gonzalez, M. P. Bioorg Med Chem 2005, 
13(9), 3269-3277. 
33. Caballero, J.; Garriga, M.; Fernandez, M. J Comput Aided Mol Des 2005, 19(11), 771-789. 
34. Caballero, J.; Fernandez, M. J Mol Model (Online) 2006, 12(2), 168-181. 
35. Caballero, J.; Fernandez, M. J Mol Model (Online) 2005, 1-14. 
36. Caballero, J.; Fernandez, L.; Abreu, J. I.; Fernandez, M. J Chem Inf Model 2006, 46(3), 1255-1268. 
37. Sanchez, R.; Grau, R. Bulletin of mathematical biology 2005, 67(5), 1017-1029. 
38. Sanchez, R.; Grau, R. Acta biotheoretica 2006, 54(1), 27-42. 
39. Sanchez, R.; Grau, R.; Morgado, E. Mathematical biosciences 2006, 202(1), 156-174. 
40. Sanchez, R.; Morgado, E.; Grau, R. Bulletin of mathematical biology 2005, 67(1), 1-14. 
41. Sanchez, R.; Morgado, E.; Grau, R. Journal of mathematical biology 2005, 51(4), 431-457. 
42. Bashford, J. D.; Jarvis, P. D. Bio Systems 2000, 57(3), 147-161. 
43. Beland, P.; Allen, T. F. Journal of theoretical biology 1994, 170(4), 359-365. 
44. Zhang, Z.; Grigorov, M. G. Proteins 2006, 62(2), 470-478. 
45. Voy, B. H.; Scharff, J. A.; Perkins, A. D.; Saxton, A. M.; Borate, B.; Chesler, E. J.; Branstetter, L. K.; 
Langston, M. A. PLoS Comput Biol 2006, 2(7), e89. 
46. Tanaka, T.; Ikeo, K.; Gojobori, T. Gene 2006, 365, 88-94. 
47. Sun, S.; Zhao, Y.; Jiao, Y.; Yin, Y.; Cai, L.; Zhang, Y.; Lu, H.; Chen, R.; Bu, D. FEBS Lett 2006, 
580(7), 1891-1896. 
48. Gelfand, M. S. Curr Opin Struct Biol 2006, 16(3), 420-429. 
49. Barabasi, A. L. Science 2005, 308(5722), 639-641. 
50. Barabasi, A. L.; Freeh, V. W.; Jeong, H.; Brockman, J. B. Nature 2001, 412(6850), 894-897. 
51. Barabasi, A. L.; Oltvai, Z. N. Nature reviews 2004, 5(2), 101-113. 
52. de Menezes, M. A.; Barabasi, A. L. Physical review letters 2004, 92(2), 028701. 
53. Dezso, Z.; Barabasi, A. L. Physical review 2002, 65(5 Pt 2), 055103. 
54. Dezso, Z.; Oltvai, Z. N.; Barabasi, A. L. Genome research 2003, 13(11), 2450-2454. 
55. Dobrin, R.; Beg, Q. K.; Barabasi, A. L.; Oltvai, Z. N. BMC bioinformatics 2004, 5, 10. 
56. Jeong, H.; Mason, S. P.; Barabasi, A. L.; Oltvai, Z. N. Nature 2001, 411(6833), 41-42. 
57. Jeong, H.; Tombor, B.; Albert, R.; Oltvai, Z. N.; Barabasi, A. L. Nature 2000, 407(6804), 651-654. 
58. Oliveira, J. G.; Barabasi, A. L. Nature 2005, 437(7063), 1251. 
59. Yu, X.; Lin, J.; Masuda, T.; Esumi, N.; Zack, D. J.; Qian, J. Nucleic Acids Res 2006, 34(3), 917-927. 
60. Carter, S. L.; Brechbuhler, C. M.; Griffin, M.; Bond, A. T. Bioinformatics 2004, 20(14), 2242-2250. 
61. Carlson, M. R.; Zhang, B.; Fang, Z.; Mischel, P. S.; Horvath, S.; Nelson, S. F. BMC Genomics 2006, 7, 
40. 
62. Zhang, B.; Horvath, S. Statistical applications in genetics and molecular biology 2005, 4, Article17. 
63. Reverter, A.; Barris, W.; McWilliam, S.; Byrne, K. A.; Wang, Y. H.; Tan, S. H.; Hudson, N.; 
Dalrymple, B. P. Bioinformatics 2005, 21(7), 1112-1120. 
64. Estrada, E. Proteomics 2006, 6(1), 35-40. 
65. Estrada, E.; Rodriguez-Velazquez, J. A. Phys Rev E Stat Nonlin Soft Matter Phys 2005, 71(5 Pt 2), 
056103. 
66. Jeong, H.; Mason, S. P.; Barabási, A.-L.; Oltvai, Z. N. Nature 2001, 411, 41–42. 
67. Yu, X.; Lin, J.; Zack, D. J.; Qian, J. Nucleic Acids Res 2006, 34(17), 4925-4936. 
68. Margolin, A. A.; Nemenman, I.; Basso, K.; Wiggins, C.; Stolovitzky, G.; Dalla Favera, R.; Califano, A. 
BMC Bioinformatics 2006, 7 Suppl 1, S7. 
69. Jonsson, P. F.; Bates, P. A. Bioinformatics 2006. 
70. Van Waterbeemd, H. Chemometric methods in molecular design; Wiley-VCH: New York, 1995. 
71. StatSoft.Inc., 2002, p STATISTICA (data analysis software system), version 6.0, 
www.statsoft.com.Statsoft. 
 17 
72. González-Díaz, H.; Molina-Ruiz, R.; Hernandez, I., 2005, p MARCH-INSIDE version 2.0 (Markovian 
Chemicals In Silico Design). Main author information requesting contact email: 
gonzalezdiazh@yahoo.es. 
73. Microsoft.Corp., 2002, p Microsoft Excel  
74. Koschützki, D., 2006, p CentiBiN Version 1.4.2, Centralities in Biological Networks ©  2004-2006 Dirk 
Koschützki Research Group Network Analysis, IPK Gatersleben, Germany. 
75. Junker, B. H.; Koschutzki, D.; Schreiber, F. BMC bioinformatics 2006, 7, 219. 
76. Cambridge.Soft., 2005, p ChemOffice, version 9.0, a CambridgeSoft Software Development Kit (SDK), 
integrating ChemDraw, ChemFinder, and Chem3D. 
77. Estrada, E.; Uriarte, E. Curr Med Chem 2001, 8, 1573-1588. 
78. Devillers, J.; Balaban, A. T., Eds. Topological Indices and Related Descriptors in QSAR and QSPR; 
Gordon and Breach The Netherlands, 1999. 
79. González-Díaz, H.; Vilar, S.; Santana, L.; Uriarte, E. Current Topics in Medicinal Chemistry 2007, 7, 
doi:1568-0266/1507. 
80. Gozalbes, R.; Galvez, J.; Garcia-Domenech, R.; Derouin, F. SAR QSAR Environ Res 1999, 10(1), 47-
60. 
81. Meneses-Marcel, A.; Marrero-Ponce, Y.; Machado-Tugores, Y.; Montero-Torres, A.; Pereira, D. M.; 
Escario, J. A.; Nogal-Ruiz, J. J.; Ochoa, C.; Aran, V. J.; Martinez-Fernandez, A. R.; Garcia Sanchez, R. 
N. Bioorg Med Chem Lett 2005, 15(17), 3838-3843. 
82. Murcia-Soler, M.; Perez-Gimenez, F.; Garcia-March, F. J.; Salabert-Salvador, M. T.; Diaz-Villanueva, 
W.; Medina-Casamayor, P. J Mol Graph Model 2003, 21(5), 375-390. 
83. Pasqualoto, K. F.; Ferreira, E. I.; Santos-Filho, O. A.; Hopfinger, A. J. J Med Chem 2004, 47(15), 3755-
3764. 
84. Marrero-Ponce, Y.; Iyarreta-Veitia, M.; Montero-Torres, A.; Romero-Zaldivar, C.; Brandt, C. A.; Avila, 
P. E.; Kirchgatter, K.; Machado, Y. J Chem Inf Model 2005, 45(4), 1082-1100. 
85. Marrero-Ponce, Y.; Castillo-Garit, J. A.; Olazabal, E.; Serrano, H. S.; Morales, A.; Castanedo, N.; 
Ibarra-Velarde, F.; Huesca-Guillen, A.; Jorge, E.; del Valle, A.; Torrens, F.; Castro, E. A. J Comput 
Aided Mol Des 2004, 18(10), 615-634. 
86. Garcia-Garcia, A.; Galvez, J.; de Julian-Ortiz, J. V.; Garcia-Domenech, R.; Munoz, C.; Guna, R.; 
Borras, R. J Antimicrob Chemother 2004, 53(1), 65-73. 
87. Cronin, M. T.; Aptula, A. O.; Dearden, J. C.; Duffy, J. C.; Netzeva, T. I.; Patel, H.; Rowe, P. H.; 
Schultz, T. W.; Worth, A. P.; Voutzoulidis, K.; Schuurmann, G. J Chem Inf Comput Sci 2002, 42(4), 
869-878. 
88. Graham, R. L.; Groetschel, M.; Lovász, L. Handbook of Combinatorics; Elsevier (North-Holland) and 
MIT Press: Amsterdam and Cambridge, 1996. 
89. Gupta, A.; Maranas, C. D.; Albert, R. Bioinformatics 2006, 22(2), 209-214. 
90. Saiz-Urra, L.; Gonzalez, M. P.; Fall, Y.; Gomez, G. Eur J Med Chem 2007, 42(1), 64-70. 
91. Podani, J.; Oltvai, Z. N.; Jeong, H. G.; Tombor, B.; Barabási, A.-L.; Szathmáry, E. Nat Genet 2001, 29, 
54-56. 
92. Tsaparas, P.; Marino-Ramirez, L.; Bodenreider, O.; Koonin, E. V.; Jordan, I. K. BMC Evol Biol 2006, 
6, 70. 
93. Brun, C.; Herrmann, C.; Guenoche, A. BMC Bioinformatics 2004, 5, 95. 
94. Junker, B. H.; Koschuetzki, D.; Schreiber, F. BMC Bioinformatics 2006, 7(1), 219. 
95. Di Santo, R.; Tafi, A.; Costi, R.; Botta, M.; Artico, M.; Corelli, F.; Forte, M.; Caporuscio, F.; Angiolella, 
L.; Palamara, A. T. J Med Chem 2005, 48(16), 5140-5153. 
96. Zhu, D.; Hero, A. O.; Cheng, H.; Khanna, R.; Swaroop, A. Bioinformatics 2005, 21(21), 4014-4020. 
97. Kamp, C.; Christensen, K. Phys Rev E Stat Nonlin Soft Matter Phys 2005, 71(4 Pt 1), 041911. 
98. Spirin, V.; Mirny, L. A. Proc Natl Acad Sci U S A 2003, 100(21), 12123-12128. 
99. Koschützki D.; Lehmann, K. A.; Peeters, L.; Richter, S.; Tenfelde-Podehl, D.; Zlotowski, O. In Network 
Analysis: Methodological Foundations, LNCS Tutorial Brandes, U.; Erlebach, T., Eds.; Springer, 2005, 
p 16-61. 
 18 
100. Valente, T. W.; Foreman, R. K. Social Networks 1998, 1, 89-105. 
101. Barabasi, A. L.; Albert, R. Science 1999, 286(5439), 509-512. 
102. Kleinberg, J. M. Nature 2000, 406(6798), 845. 
103. Kleinberg, J.; Lawrence, S. Science 2001, 294(5548), 1849-1850. 
104. Barabasi, A. L.; Bonabeau, E. Scientific American 2003, 288(5), 60-69. 
 
 
 
